Kari McKnight
Medical · Williamsburg, KYNPI 1912128125
Payments from drug & device makers
Across 122 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$286
- AstraZeneca$274
- Novo Nordisk$228
- Bayer$208
- Abbott$153
- GSK$143
- plus $912 from 20 others
What the payments were for
- Food & beverage$2,203100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,203 in reported general payments places this provider in the 65th percentile of 222 medical providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $119,354 |
| MounjaroTirzepatide | 82 | $85,700 |
| XifaxanRifaximin | 21 | $70,808 |
| LinzessLinaclotide | 85 | $52,211 |
| EliquisApixaban | 56 | $48,042 |
| RybelsusSemaglutide | 28 | $41,859 |
| JardianceEmpagliflozin | 33 | $25,342 |
| EntrestoSacubitril/Valsartan | 30 | $25,330 |
| JanuviaSitagliptin Phosphate | 30 | $22,425 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $21,732 |
| VraylarCariprazine Hcl | 13 | $18,169 |
| UbrelvyUbrogepant | 15 | $15,589 |
| XareltoRivaroxaban | 26 | $15,420 |
| ZenpepLipase/Protease/Amylase | 11 | $14,475 |
| TradjentaLinagliptin | 28 | $14,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $228 | $161,213152 claims |
| AbbVieLinzess, Vraylar, Ubrelvy | $286 | $85,969113 claims |
| Lilly USA, LLCMounjaro | $62 | $85,70082 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $18 | $70,80821 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $28 | $49,33675 claims |
| MerckJanuvia | $62 | $22,42530 claims |
| BayerKerendia | $208 | $13,50721 claims |
| AstraZenecaBreztri Aerosphere | $274 | $9,60215 claims |
| GSKTrelegy Ellipta | $143 | $7,38712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 222 medical providers in Kentucky.
Other medical in Williamsburg
- Aaron PetreyWilliamsburg$3K
- Mikal BaileyPaducah$84K
- Kyle HeraldBowling Green$65K
- Chasity HesterLexington$16K
- Alexandra HuettLouisville$13K
- Danny ThackerFrankfort$11K
- Jessica FrizzellPaducah$10K
- Terry SmithHazard$10K
- Ashley HenegarGeorgetown$10K
- Rachel CrowleyPaducah$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.